Maite Bourlon: PARPi for prostate cancer
Maite Bourlon, the Head of the Urologic Oncology Clinic at Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán and Editorial Board Member of OncoDaily, shared on X (Twitter):
“Great! “PARPi for prostate cancer”
🔹1st targeted therapy for advanced disease
✅ TRITON-3 & PROFOUND showed benefit in mCRPC w DDR alt
‼️PROPEL, TALAPRO-2 & MAGNITUDE in 1L mCRPC but mostly unexposed to ARSi
Is PARPi rechallenge possible?”
Paper authored by Maria Theresa (Maite) Bourlon, Paola Valdez and Elena Castro. Development of PARP inhibitors in advanced prostate cancer. Therapeutic Advances in Medical Oncology
Source: Maite Bourlon / X
Maria T Bourlon is an Associate Professor and Head of the Urologic Oncology Clinic at Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico. She is the Director of the Genitourinary Cancers Program at Universidad Nacional Autónoma de México. Dr. Bourlon is the chair-elect of the American Society of Clinical Oncology IDEA Steering Group and in 2023 received the prestigious ASCO CCF International Women Who Conquer Cancer (WWCC) Mentorship Award. She is on the Editorial Board of OncoDaily.
